ASTRAZENECA PLC vs BRISTOL-MYERS SQUIBB COMPANY, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where AZN and BMY diverge most: on revenue growth, AZN reads +12.1% and BMY reads +3.1%; on debt / equity, AZN reads 0.57 and BMY reads 1.97. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | AZN | BMY |
|---|---|---|
| Price | $159.18 | $59.11 |
| Market cap | $246.7B | $121.1B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| P/E | 24.1 | 13.0 |
| P/B | 5.06 | 5.42 |
| P/S | 4.20 | 2.46 |
| EV/EBITDA | 14.3 | 47.8 |
| Revenue growth | +12.1% | +3.1% |
| Gross margin | 81.9% | — |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | 18.9% |
| Return on equity | 21.0% | 41.6% |
| Return on assets | 9.0% | 10.6% |
| Return on invested capital | 14.8% | — |
| FCF yield | 4.8% | 9.4% |
| Dividend yield | — | 4.2% |
| Debt / equity | 0.57 | 1.97 |
| Current ratio | 0.94 | 1.53 |
| Altman Z (solvency) | 3.29 | 2.13 |
| Piotroski F (quality) | 8 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.